Enterobacter aerogenes

Jump to: navigation, search
Enterobacter aerogenes
Scientific classification
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Gamma Proteobacteria
Order: Enterobacteriales
Family: Enterobacteriaceae
Genus: Enterobacter
Binomial name
Enterobacter aerogenes


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Enterobacter aerogenes is a Gram-negative, oxidase negative, catalase positive, rod-shaped bacterium.

E. aerogenes is a nosocomial pathogen that causes opportunistic skin and tissue infections. Some strains can become very treatment resistant, a result of their colonization within hospital environments.

Most of the infections caused by E. aerogenes result from specific antibiotic treatments, venous catheter insertions, and/or surgical procedures. E. aerogenes is generally found in the human intestinal tract and does not generally cause disease in healthy individuals. It has been found to live in various wastes, hygenic chemicals, and soil. The bacterium also has some commercial significance - the hydrogen gas produced during fermentation has been experimented with in the production of molasses.

One possible identification code generated by testing E. aerogenes using an API strip is 5 305 773.

Antibiotic Regimen

  • 1. Empiric antimicrobial therapy pending in vitro susceptibility
  • 1.1 Non–life-threatening infections or MDR-GNB prevalence < 20%
  • 1.2 Life-threatening infections or MDR-GNB prevalence > 20%
  • 2. In vitro susceptibility available
  • 2.1 Susceptible to all tested agents
  • 2.2 Extended spectrum beta-lactamase (ESBL)-producing Enterobacter spp.
  • Preferred regimen: Meropenem 0.5–1 g IV q8h
  • Alternative regimen (1): Imipenem 500 mg IV q6h
  • Alternative regimen (2): Doripenem 500 mg IV q8h
  • Alternative regimen (3): Ertapenem 1 g IV q24h
  • Alternative regimen (4): Cefepime 2 g IV q8h (if MIC ≤ 1 μg/mL)
  • 2.3 Resistant to all tested agents

References

  1. Sanders, W. E.; Sanders, C. C. (1997-04). "Enterobacter spp.: pathogens poised to flourish at the turn of the century". Clinical Microbiology Reviews. 10 (2): 220–241. ISSN 0893-8512. PMC 172917. PMID 9105752. Check date values in: |date= (help)
  2. Jacoby, George A. (2009-01). "AmpC beta-lactamases". Clinical Microbiology Reviews. 22 (1): 161–182. doi:10.1128/CMR.00036-08. ISSN 1098-6618. PMC 2620637. PMID 19136439. Check date values in: |date= (help)
  3. Paterson, David L.; Bonomo, Robert A. (2005-10). "Extended-spectrum beta-lactamases: a clinical update". Clinical Microbiology Reviews. 18 (4): 657–686. doi:10.1128/CMR.18.4.657-686.2005. ISSN 0893-8512. PMC 1265908. PMID 16223952. Check date values in: |date= (help)
  4. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
  5. Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
Wikispecies-logo.svg
Wikispecies has information related to:

Template:Proteobacteria-stub


Linked-in.jpg